Looks at nerve, immune and thinking markers in relapsing-remitting multiple sclerosis
Studies markers of multiple sclerosis in adults, including some already on treatment.
Plain-language title generated from the registry record
Registry title: Investigation of Subclinical Markers of Multiple Sclerosis
Key facts
- Where
- Split, CroatiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT04604041, who can take part
Where in Croatia
- University of Split School of MedicineSplit, CroatiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Split, School of Medicine
- Trial code
- NCT04604041
- Record updated
- 2 October 2023
- Original description
Transcranial magnetic stimulation (TMS) studies reported consistent and substantial impairments in the central nervous system (CNS) in multiple sclerosis (MS). Studies of peripheral nervous system (PNS) function comprising electromyoneurography (EMNG) reported impairments of the PNS in MS that were less pronounced and inconsistent. Neurophysiological studies are generally small and cross-sectional and with the poor grouping of MS patients according to MS type.Read full original descriptionShow less
Investigation of Subclinical Markers of Multiple Sclerosis
Transcranial magnetic stimulation (TMS) studies reported consistent and substantial impairments in the central nervous system (CNS) in multiple sclerosis (MS). Studies of peripheral nervous system (PNS) function comprising electromyoneurography (EMNG) reported impairments of the PNS in MS that were less pronounced and inconsistent. Neurophysiological studies are generally small and cross-sectional and with the poor grouping of MS patients according to MS type.
The objective of the study is to investigate clinical, neurophysiological, and immunological markers in relapsing-remitting MS patients, and in patients with relapsing-remitting MS treated with immunomodulation. The results of the study may contribute to a better understanding of the pathophysiology of multiple sclerosis and can provide guidance in the diagnosis and treatment of patients with relapsing-remitting MS.
Inclusion: Subjects with a documented diagnosis of relapsing-remitting MS according to the Mc Donald criteria (2005) and with EDSS achievement of 0-3.5 according to the modified Kurtzke's EDSS (Expanded disability status scale) for the assessment of neurological function and incapacity of patients with multiple sclerosis.
Exclusion: Patients with metals in the body (e.g. pacemaker, dentures); Patients with new pregnancies (verbally confirmed); Patients with new head trauma; Subjects unwilling to sign a consent or follow study procedures.